Patients with ovarian serous adenocarcinomas showed eIF6 overexpression and a correlation with patients’ overall survival (Golob-Schwarzl et al. 2017; Flavin et al. 2008). This evidence concerns the gene EIF6 and ovarian serous adenocarcinoma.